Preferred Label : HIV envelope protein gp41;
MeSH definition : Transmembrane envelope protein of the HUMAN IMMUNODEFICIENCY VIRUS which is encoded
by the HIV env gene. It has a molecular weight of 41,000 and is glycosylated. The
N-terminal part of gp41 is thought to be involved in CELL FUSION with the CD4 ANTIGENS
of T4 LYMPHOCYTES, leading to syncytial formation. Gp41 is one of the most common
HIV antigens detected by IMMUNOBLOTTING.;
MeSH synonym : env protein gp41, hiv; htlv-iii gp41; hiv transmembrane protein gp41; gp41 envelope protein, hiv; gp41(hiv); envelope protein gp41, hiv;
Is substance : O;
Origin ID : D015700;
UMLS CUI : C0019692;
Allowable qualifiers
Currated CISMeF NLP mapping
Record concept(s)
Related MeSH Supplementary Concept(s)
- SJ 2176 [MeSH Supplementary Concept]
Semantic type(s)
UMLS correspondences (same concept)
Transmembrane envelope protein of the HUMAN IMMUNODEFICIENCY VIRUS which is encoded
by the HIV env gene. It has a molecular weight of 41,000 and is glycosylated. The
N-terminal part of gp41 is thought to be involved in CELL FUSION with the CD4 ANTIGENS
of T4 LYMPHOCYTES, leading to syncytial formation. Gp41 is one of the most common
HIV antigens detected by IMMUNOBLOTTING.
https://pharmacomedicale.org/medicaments/par-specialites/item/autres-antiretroviraux
2016
false
false
false
France
French
drug information
hiv fusion inhibitors
hiv infections
enfuvirtide
maraviroc
CCR5 Receptor Antagonists
Raltegravir Potassium
raltegravir
HIV integrase inhibitors
anti-retroviral agents
peptide fragments
HIV envelope protein gp41
cyclohexanes
triazoles
Enfuvirtide
Maraviroc
---
http://www.meddispar.fr/medicaments/3622185
2008
France
French
HIV envelope protein gp41
injections
legislation, drug
drug prescriptions
peptide fragments
enfuvirtide
drug information
Enfuvirtide
---
https://www.ema.europa.eu/medicines/human/EPAR/Fuzeon
2008
United Kingdom
English
French
syndication feed
Contraindications, Procedure
peptide fragments
hiv fusion inhibitors
hiv fusion inhibitors
hiv fusion inhibitors
drug interactions
treatment outcome
drug evaluation, preclinical
pregnancy
breast feeding
drug labeling
drug approval
HIV-1
drug therapy, combination
HIV envelope protein gp41
hiv fusion inhibitors
acquired immunodeficiency syndrome
peptide fragments
peptide fragments
HIV envelope protein gp41
hiv fusion inhibitors
hiv infections
HIV envelope protein gp41
peptide fragments
hiv fusion inhibitors
HIV envelope protein gp41
HIV envelope protein gp41
HIV envelope protein gp41
peptide fragments
peptide fragments
injections, subcutaneous
adult
adolescent
aged
child
powders
enfuvirtide
drug evaluation
summary of product characteristics
package leaflet
Contraindications, Drug
Enfuvirtide
---
https://www.cadth.ca/sites/default/files/pdf/260_enfuvirtide_cetap_f.pdf
2003
Canada
French
acquired immunodeficiency syndrome
hiv infections
acquired immunodeficiency syndrome
hiv infections
peptide fragments
HIV envelope protein gp41
hiv fusion inhibitors
hiv fusion inhibitors
peptide fragments
HIV envelope protein gp41
treatment outcome
canada
clinical trials as topic
HIV envelope protein gp41
hiv fusion inhibitors
peptide fragments
enfuvirtide
peptide fragments
HIV envelope protein gp41
journal article
table
drug evaluation
Enfuvirtide
---